Subclinical metabolic and cardiovascular abnormalities in autosomal dominant polycystic kidney disease

被引:6
作者
Chirumamilla, Radha [1 ]
Mina, Diana [1 ]
Siyahian, Salpi [1 ]
Park, Meyeon [1 ]
机构
[1] Univ Calif San Francisco, Dept Med, Div Nephrol, UCSF PKD Ctr Excellence, San Francisco, CA 94143 USA
关键词
autosomal dominant kidney disease; meta-bolic abnormalities; insulin resistance; hyperlipidemia; left ventricular hypertrophy; oxidative stress; calorie restriction; LEFT-VENTRICULAR MASS; POSTTRANSPLANT DIABETES-MELLITUS; RENAL CYSTIC-DISEASE; INSULIN-RESISTANCE; RISK-FACTOR; GLUCOSE-INTOLERANCE; ARTERIAL STIFFNESS; DIETARY DEFICIENCY; RAT-KIDNEY; TRANSPLANTATION;
D O I
10.5414/CN109233
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disease. It carries high lifetime morbidity not only due to chronic kidney disease, but also due to a higher risk of cardiovascular death. Multiple metabolic abnormalities associated with ADPKD including insulin resistance and hyperlipidemia as well as subclinical cardiovascular abnormalities, such as left ventricular hypertrophy (LVH), contribute to this cardiovascular risk. These conditions may manifest before evidence of worsening estimated glomerular filtration rate (eGFR). Renal oxidative stress also occurs early in the disease and is a driver of ADPKD progression. Animal models have shown that calorie restriction may mitigate these inflammatory processes. Further research is required to show whether attenuation of metabolic abnormalities associated with ADPKD may improve renal and cardiovascular morbidity.
引用
收藏
页码:237 / 245
页数:9
相关论文
共 50 条
[41]   Autosomal dominant polycystic kidney disease, more than a renal disease [J].
Torra, R. .
MINERVA ENDOCRINOLOGICA, 2014, 39 (02) :79-87
[42]   Management of ESRD in Patients With Autosomal Dominant Polycystic Kidney Disease [J].
Alam, Ahsan ;
Perrone, Ronald D. .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2010, 17 (02) :164-172
[43]   Interventions for preventing the progression of autosomal dominant polycystic kidney disease [J].
Bolignano, Davide ;
Palmer, Suetonia C. ;
Ruospo, Marinella ;
Zoccali, Carmine ;
Craig, Jonathan C. ;
Strippoli, Giovanni F. M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (07)
[44]   Interventions for preventing the progression of autosomal dominant polycystic kidney disease [J].
St Pierre, Kitty ;
Cashmore, Brydee A. ;
Bolignano, Davide ;
Zoccali, Carmine ;
Ruospo, Marinella ;
Craig, Jonathan C. ;
Strippoli, Giovanni F. M. ;
Mallett, Andrew J. ;
Green, Suetonia C. ;
Tunnicli, David J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (10)
[45]   The spectrum of autosomal dominant polycystic kidney disease in children and adolescents [J].
Reddy, Bharathi V. ;
Chapman, Arlene B. .
PEDIATRIC NEPHROLOGY, 2017, 32 (01) :31-42
[46]   Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder? [J].
De Rechter, Stephanie ;
Breysem, Luc ;
Mekahli, Djalila .
FRONTIERS IN PEDIATRICS, 2017, 5
[47]   Novel targets for the treatment of autosomal dominant polycystic kidney disease [J].
Belibi, Franck A. ;
Edelstein, Charles L. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (03) :315-328
[48]   Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease [J].
Rahbari-Oskoui, Frederic ;
Williams, Olubunmi ;
Chapman, Arlene .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (12) :2194-2201
[49]   Optimal care of autosomal dominant polycystic kidney disease patients [J].
Schrier, RW .
NEPHROLOGY, 2006, 11 (02) :124-130
[50]   Autosomal dominant polycystic kidney disease - Clinical and genetic aspects [J].
Bogdanova, N ;
Markoff, A ;
Horst, J .
KIDNEY & BLOOD PRESSURE RESEARCH, 2002, 25 (05) :265-283